Rafarma Pharmaceuticals Stock Return On Equity
| RAFA Stock | USD 0.06 0.01 8.96% |
Rafarma Pharmaceuticals fundamentals help investors to digest information that contributes to Rafarma Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rafarma Pink Sheet. The fundamental analysis module provides a way to measure Rafarma Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rafarma Pharmaceuticals pink sheet.
Rafarma |
Rafarma Pharmaceuticals Company Return On Equity Analysis
Rafarma Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rafarma Pharmaceuticals Return On Equity | -7.0E-4 |
Most of Rafarma Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rafarma Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Rafarma Pharmaceuticals has a Return On Equity of -7.0E-4. This is 100.0% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 99.77% lower than that of the firm.
Rafarma Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rafarma Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rafarma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rafarma Pharmaceuticals by comparing valuation metrics of similar companies.Rafarma Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Rafarma Fundamentals
| Return On Equity | -7.0E-4 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.88) % | |||
| Operating Margin | (0.81) % | |||
| Current Valuation | 7.89 M | |||
| Price To Earning | (1.29) X | |||
| Price To Sales | 857.77 X | |||
| Net Income | (14.85 K) | |||
| Book Value Per Share | 40.49 X | |||
| Cash Flow From Operations | (1 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -0.39 | |||
| Market Capitalization | 110.29 M | |||
| Total Asset | 460.33 M | |||
| Retained Earnings | (2.38 M) | |||
| Current Liabilities | 292 K | |||
| Net Asset | 460.33 M |
About Rafarma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rafarma Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rafarma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rafarma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rafarma Pink Sheet
Rafarma Pharmaceuticals financial ratios help investors to determine whether Rafarma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rafarma with respect to the benefits of owning Rafarma Pharmaceuticals security.